Photoactivation of MDM2 Inhibitors: Controlling Protein–Protein Interaction with Light
暂无分享,去创建一个
Wiktor Szymanski | René H Medema | Mickel J Hansen | Ben L Feringa | R. Medema | B. Feringa | W. Szymański | M. J. Hansen | Femke M Feringa | Piermichele Kobauri | Piermichele Kobauri | F. Feringa | Femke M. Feringa
[1] R. Gropeanu,et al. Ethyl substituted coumarin-4-yl derivatives as photoremovable protecting groups for amino acids with improved stability for SPPS , 2012 .
[2] Wiktor Szymanski,et al. Wavelength-selective cleavage of photoprotecting groups: strategies and applications in dynamic systems. , 2015, Chemical Society reviews.
[3] T. Poulsen,et al. Ester coupling reactions--an enduring challenge in the chemical synthesis of bioactive natural products. , 2015, Natural product reports.
[4] B. Kuhn,et al. Practical Synthesis of MDM2 Antagonist RG7388. Part 2: Development of the Cu(I) Catalyzed [3 + 2] Asymmetric Cycloaddition Process for the Manufacture of Idasanutlin , 2016 .
[5] Jeffrey T. Chang,et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.
[6] Scott W. Lowe,et al. Putting p53 in Context , 2017, Cell.
[7] S. Nonell,et al. Development of Green/Red-Absorbing Chromophores Based on a Coumarin Scaffold That Are Useful as Caging Groups. , 2017, The Journal of organic chemistry.
[8] J. Moslehi,et al. Cardiovascular Toxic Effects of Targeted Cancer Therapies. , 2016, The New England journal of medicine.
[9] A. Levine,et al. The p53 pathway: positive and negative feedback loops , 2005, Oncogene.
[10] Zizhong Li,et al. Practical Synthesis of MDM2 Antagonist RG7388. Part 1: A Cu(II)-Catalyzed Asymmetric [3 + 2] Cycloaddition , 2016 .
[11] Jean-Yves Blay,et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. , 2012, The Lancet. Oncology.
[12] M. Oren,et al. Mdm2 promotes the rapid degradation of p53 , 1997, Nature.
[13] A. Massaguer,et al. A Green Light-Triggerable RGD Peptide for Photocontrolled Targeted Drug Delivery: Synthesis and Photolysis Studies. , 2016, The Journal of organic chemistry.
[14] R. Bernards,et al. Enabling personalized cancer medicine through analysis of gene-expression patterns , 2008, Nature.
[15] R. Medema,et al. Transient activation of p53 in G2 phase is sufficient to induce senescence. , 2014, Molecular cell.
[16] David M. Thomas,et al. Clinical Overview of MDM2/X-Targeted Therapies , 2016, Front. Oncol..
[17] D. Trauner,et al. A roadmap to success in photopharmacology. , 2015, Accounts of Chemical Research.
[18] D. Chenoweth,et al. Synthesis and properties of lysosome-specific photoactivatable probes for live-cell imaging , 2015, Chemical science.
[19] Hirofumi Tanaka,et al. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53 , 1997, FEBS letters.
[20] H. Möller,et al. Spatio-temporal control of cellular uptake achieved by photoswitchable cell-penetrating peptides. , 2016, Chemical communications.
[21] S. Agarwal,et al. The MDM2 small-molecule inhibitor RG7388 leads to potent tumor inhibition in p53 wild-type neuroblastoma , 2015, Cell Death Discovery.
[22] R. Givens,et al. Photoremovable Protecting Groups in Chemistry and Biology: Reaction Mechanisms and Efficacy , 2012, Chemical reviews.
[23] B. Feringa,et al. Orthogonal control of antibacterial activity with light. , 2014, ACS chemical biology.
[24] Alan R. Fersht,et al. Awakening guardian angels: drugging the p53 pathway , 2009, Nature Reviews Cancer.
[25] L. Vassilev,et al. In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.
[26] Bert Vogelstein,et al. p53 function and dysfunction , 1992, Cell.
[27] Gooitzen M van Dam,et al. Emerging Targets in Photopharmacology. , 2016, Angewandte Chemie.
[28] Stephen N. Jones,et al. Regulation of p53 stability by Mdm2 , 1997, Nature.
[29] Jing Zhang,et al. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. , 2013, Journal of medicinal chemistry.
[30] N. Emptage,et al. Wavelength-orthogonal photolysis of neurotransmitters in vitro. , 2012, Chemical communications.